Business Context and Reporting Period
Relay Therapeutics, Inc. (RLAY) filed a Form 8-K on December 11, 2020, reporting the entry into a definitive Collaboration and License Agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd (collectively, "Licensee"). The agreement focuses on the development and commercialization of RLY-1971, an oral, small molecule inhibitor of SHP2 currently in a Phase 1a clinical trial for advanced solid tumors.
Key Financial Metrics
This filing details a strategic partnership rather than periodic financial results. Key financial terms include:
- Upfront Payment: $75 million.
- Near-Term Payments: Eligible to receive an additional $25 million.
- Profit-Cost Share Option: Relay may elect to fund 50% of U.S. development costs in exchange for 50% of U.S. net profits/losses. If elected, potential additional milestones total up to $410 million (non-U.S.) plus tiered royalties (low-to-mid teens) on non-U.S. sales.
- Standard Option (No Profit-Cost Share): If the option is not exercised, Licensee bears all development costs (excluding Phase 1a). Relay is eligible for up to $695 million in worldwide milestones and tiered royalties (low-to-mid teens) on worldwide net sales.
- Additional Royalties: Eligible for additional royalties if RLY-1971 and GDC-6036 are approved in combination.
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity for the reporting period.
Material Changes
The primary material change is the execution of the collaboration agreement, which grants Licensee an exclusive, worldwide, royalty-bearing license to develop and commercialize RLY-1971. Under the agreement:
- Licensee assumes responsibility for all subsequent clinical development and commercialization of RLY-1971, including combination trials with GDC-6036.
- Relay retains the right to develop RLY-1971 in combination with its own compounds targeting FGFR2 (e.g., RLY-4008) or PI3K alpha.
- Relay is restricted from developing other SHP2 inhibitors outside of the agreement's scope.
Outlook, Risks, and Contingencies
Management Commentary and Outlook: The company plans to host a conference call on December 14, 2020, to discuss the agreement. The partnership aims to accelerate the development of RLY-1971 while providing Relay with significant potential future revenue streams through milestones and royalties.
Risks and Contingencies:
- Termination: The agreement may be terminated for material breach, insolvency, or failure to obtain merger control. Licensee may terminate for convenience; Relay may terminate for patent challenges or lack of activity by Licensee.
- Regulatory Approval: Future payments and commercialization depend on the successful completion of clinical trials and regulatory approval of RLY-1971.
- Profit-Cost Share Risk: If Relay opts into the Profit-Cost Share, it assumes financial risk for U.S. development costs and potential net losses.
Investor Verification Checklist
- Verify the exact terms of the "Profit-Cost Share" election window and the specific financial implications of opting in versus out.
- Confirm the status and timeline of the ongoing Phase 1a clinical trial for RLY-1971.
- Review the full text of the Collaboration and License Agreement (to be filed as an exhibit) for redacted confidential terms.
- Monitor the December 14, 2020, press release and conference call for management's specific strategic rationale and financial impact assessment.
- Assess the potential impact of the exclusivity clause on Relay's ability to pursue other SHP2 inhibitor candidates.